IP Library Patent Application 19303894
Patent Application
App. No. 19/303,894

SEMIFLUORINATED ALKANE TETRACYCLINE COMBINATION COMPOSITIONS FOR TREATMENT OF MALAR EDEMA

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
19/303,894
Abstract

Disclosed herein are injectable compositions, such as nonaqueous liquid injectable compositions, comprising at least one tetracycline antibiotic, such as doxycycline, and at least one semifluorinated alkane, such as 1-perfluorohexyloctane (F6H8), as well as methods of treatment or prevention of malar edema, with such compositions. The injectable compositions may further be provided in a container closure system, such as a polypropylene (PP) pre-filled syringe, or in a kit.

Claims (23)

1 . An injectable composition comprising: (a) at least one tetracycline antibiotic and (b) at least one semifluorinated alkane.

2 . The injectable composition according to any one of claim 1 , wherein the at least one tetracycline antibiotic is chosen from doxycycline, demeclocycline, minocycline, tetracycline, or any combination thereof.

3 . The injectable composition according to claim 1 , wherein the at least one tetracycline antibiotic comprises doxycycline.

4 . The injectable composition according to claim 1 , wherein the at least one tetracycline antibiotic consists essentially of doxycycline.

5 . The injectable composition according to claim 4 , wherein the at least one tetracycline antibiotic is included in the composition at a concentration of from about 0.005% (w/w) to about 5% (w/w).

6 . The injectable composition according to claim 1 , wherein the at least one semifluorinated alkane is a compound composed of at least one perfluorinated hydrocarbon segment (F-segment) and at least one non-fluorinated hydrocarbon segment (H-segment) according to the formula FnHm, wherein the F-segments and the H-segments are linear or branched and wherein n and m, which may be the same or different, are independently chosen from 3 to 20 carbon atoms.

7 . The injectable composition according to claim 1 , wherein the at least one semifluorinated alkane is chosen from F4H5, F4H6, F5H6, F5H7, F6H6, F6H7, F6H8, or any combination thereof.

8 . The injectable composition according to claim 1 , wherein the at least one semifluorinated alkane comprises 1-perfluorohexyl-octane (F6H8).

9 . The injectable composition according to claim 1 , wherein the at least one semifluorinated alkane consists essentially of 1-perfluorohexyl-octane (F6H8).

10 . The injectable composition according to claim 1 , wherein (a) the at least one tetracycline antibiotic is chosen from doxycycline, demeclocycline, minocycline, tetracycline, or any combination thereof and (b) the at least one semifluorinated alkane is chosen from F4H5, F4H6, F5H6, F5H7, F6H6, F6H7, F6H8, or any combination thereof.

11 . The injectable composition according to claim 1 , wherein (a) the at least one tetracycline antibiotic comprises doxycycline and (b) the at least one semifluorinated alkane comprises F6H8.

12 . The injectable composition according to claim 1 , wherein (a) the at least one tetracycline antibiotic consists essentially of doxycycline and (b) the at least one semifluorinated alkane consists essentially of F6H8.

13 . The injectable composition according to claim 1 , wherein the composition is liquid.

14 . The injectable composition according to claim 13 , wherein the composition is nonaqueous.

15 . The injectable composition according to claim 14 , wherein the composition is stable.

16 . The injectable composition according to claim 1 , wherein the composition further comprises at least one non-therapeutic component and/or pharmaceutically acceptable excipient.

17 . The injectable composition according to claim 1 , wherein the composition further comprises at least one additional therapeutic agent chosen from redness reduction agents, NSAIDS, steroids, local anesthetics, antihistamines, anti-inflammatory agents, anti-allergens, or any combination thereof.

18 . A method for the treatment or temporary prevention of malar edema comprising administering via injection to a patient in need thereof an effective amount of an injectable composition comprising (a) at least one tetracycline antibiotic and (b) at least one semifluorinated alkane.

19 . The method according to claim 18 , wherein (a) the at least one tetracycline antibiotic is chosen from doxycycline, demeclocycline, minocycline, tetracycline, or any combination thereof and (b) the at least one semifluorinated alkane is chosen from F4H5, F4H6, F5H6, F5H7, F6H6, F6H7, F6H8, or any combination thereof.

20 . The method according to claim 19 , wherein (a) the at least one tetracycline antibiotic comprises doxycycline and (b) the at least one semifluorinated alkane comprises F6H8.

21 . The method according to claim 20 , wherein (a) the at least one tetracycline antibiotic consists essentially of doxycycline and (b) the at least one semifluorinated alkane consists essentially of F6H8.

22 . The method according to claim 1 , wherein the injectable composition is nonaqueous.

23 . The method according to claim 1 , wherein the injectable composition is administered to the patient in combination with an effective amount of at least one additional therapeutic agent chosen from redness reduction agents, NSAIDS, steroids, local anesthetics, antihistamines, anti-inflammatory agents, anti-allergens, or any combination thereof.

Assignments (3)
INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Dec 23, 2025
From: BAUSCH + LOMB IRELAND LIMITED
To: JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT
Reel/Frame 074050/0573 →
INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Dec 23, 2025
From: BAUSCH + LOMB IRELAND LIMITED
To: CITIBANK, N.A., AS NOTES COLLATERAL AGENT
Reel/Frame 074050/0682 →
INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Dec 23, 2025
From: BAUSCH + LOMB IRELAND LIMITED
To: CITIBANK, N.A., AS NOTES COLLATERAL AGENT
Reel/Frame 074050/0709 →